Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and ...

Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...

Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with that terminology, I'd wager that you're ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.